{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:05:48Z","timestamp":1794002748946,"version":"4.8.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic Arizona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.critrevonc.2025.104648","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T07:28:50Z","timestamp":1738394930000},"page":"104648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["CAR T-cell therapy landscape in pediatric, adolescent and young adult oncology \u2013 A comprehensive analysis of clinical trials"],"prefix":"10.1016","volume":"209","author":[{"given":"David A.","family":"Mart\u00ednez-Gamboa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea","family":"Hans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eider","family":"Moreno-Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juana","family":"Figueroa-Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Esteban","family":"Garcia-Robledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Vargas-Cely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela A.","family":"Castro-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta H.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Januario E.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10254","key":"10.1016\/j.critrevonc.2025.104648_bib1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104648_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15143537","article-title":"Pediatric cancers: insights and novel therapeutic approaches","volume":"15","author":"Agarwal","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104648_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40164-023-00435-w","article-title":"Current approaches to develop \"off-the-shelf\" chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review","volume":"12","author":"Aparicio","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104648_bib4","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104648_bib5","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.4049\/jimmunol.176.7.3885","article-title":"Cutting edge: diminished T cell TLR expression and function modulates the immune response in human filarial infection","volume":"176","author":"Babu","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104648_bib6","article-title":"Non-viral chimeric antigen receptor (CAR) T cells going viral","volume":"18","author":"Balke-Want","year":"2023","journal-title":"Immunoncol. Technol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104648_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112667","article-title":"Systematic review of available CAR-T cell trials around the world","volume":"14","author":"Barros","year":"2022","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104648_bib8","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0959-8049(97)00249-9","article-title":"The U.S. pediatric cancer clinical trials programmes: international implications and the way forward","volume":"33","author":"Bleyer","year":"1997","journal-title":"Eur. J. Cancer"},{"issue":"18 Pt 1","key":"10.1016\/j.critrevonc.2025.104648_bib9","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","article-title":"Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts","volume":"13","author":"Brentjens","year":"2007","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104648_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2019.06.036","article-title":"Understanding and managing large B cell lymphoma relapses after CAR T cell therapy","author":"Byrne","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"34","key":"10.1016\/j.critrevonc.2025.104648_bib11","doi-asserted-by":"crossref","first-page":"12640","DOI":"10.1073\/pnas.0405025101","article-title":"Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis","volume":"101","author":"Castriconi","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104648_bib12","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104648_bib13","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/eji.200939627","article-title":"TLR2 engagement on memory CD8(+) T cells improves their cytokine-mediated proliferation and IFN-gamma secretion in the absence of Ag","volume":"39","author":"Cottalorda","year":"2009","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104648_bib14","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1002\/eji.200636181","article-title":"TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation","volume":"36","author":"Cottalorda","year":"2006","journal-title":"Eur. J. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104648_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092523","article-title":"Bispecific chimeric antigen receptor T cell therapy for B cell malignancies and multiple myeloma","volume":"12","author":"Cronk","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104648_bib16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104648_bib17","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.pcl.2020.07.013","article-title":"The future of childhood cancer survivorship: challenges and opportunities for continued progress","volume":"67","author":"Dixon","year":"2020","journal-title":"Pedia Clin. North Am."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104648_bib18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF00820666","article-title":"The T-body approach: potential for cancer immunotherapy","volume":"18","author":"Eshhar","year":"1996","journal-title":"Springe Semin Immunopathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104648_bib19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4049\/jimmunol.172.1.104","article-title":"Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain","volume":"172","author":"Finney","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104648_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2014.21","article-title":"Pre-TCR\u03b1 supports CD3-dependent reactivation and expansion of TCR\u03b1-deficient primary human T-cells","volume":"1","author":"Galetto","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"25","key":"10.1016\/j.critrevonc.2025.104648_bib21","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104648_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034629","article-title":"Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)","volume":"10","author":"George","year":"2020","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104648_bib23","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1182\/blood-2002-04-1041","article-title":"Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors","volume":"100","author":"Haynes","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104648_bib24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0b013e318194a6e8","article-title":"Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy","volume":"32","author":"Hollyman","year":"2009","journal-title":"J. Immunother."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104648_bib25","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.4049\/jimmunol.167.2.1090","article-title":"CD4+\u2009T cells engrafted with a recombinant immunoreceptor efficiently lyse target cells in a MHC antigen- and Fas-independent fashion","volume":"167","author":"Hombach","year":"2001","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104648_bib26","doi-asserted-by":"crossref","first-page":"6715","DOI":"10.4049\/jimmunol.178.11.6715","article-title":"Cutting edge: TLR2 directly triggers Th1 effector functions","volume":"178","author":"Imanishi","year":"2007","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104648_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7070172","article-title":"Tumor B7-H3 (CD276) expression and survival in pancreatic cancer","volume":"7","author":"Inamura","year":"2018","journal-title":"J. Clin. Med."},{"issue":"27","key":"10.1016\/j.critrevonc.2025.104648_bib28","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene Ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104648_bib29","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bcp.12305","article-title":"Clinical trials in children","volume":"79","author":"Joseph","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104648_bib30","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1586\/ecp.09.40","article-title":"Challenges in conducting clinical trials in children: approaches for improving performance","volume":"2","author":"Kern","year":"2009","journal-title":"Expert Rev. Clin. Pharm."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104648_bib31","doi-asserted-by":"crossref","first-page":"96","DOI":"10.46989\/001c.94386","article-title":"The implementation of chimeric antigen receptor (CAR) T-cell therapy in pediatric patients: where did we come from, where are we now, and where are we going?","volume":"6","author":"Knight E","year":"2024","journal-title":"Clin. Hematol. Int."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104648_bib32","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1073\/pnas.0400171101","article-title":"TLR2 is expressed on activated T cells as a costimulatory receptor","volume":"101","author":"Komai-Koma","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104648_bib33","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1158\/2159-8290.CD-20-0779","article-title":"Opportunities and challenges in drug development for pediatric cancers","volume":"11","author":"Laetsch","year":"2021","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104648_bib34","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104648_bib35","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/leu.2017.249","article-title":"Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells","volume":"32","author":"Lai","year":"2018","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104648_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184528","article-title":"Surfaceome profiling of rhabdomyosarcoma reveals B7-H3 as a mediator of immune evasion","volume":"13","author":"Lavoie","year":"2021","journal-title":"Cancers"},{"issue":"9967","key":"10.1016\/j.critrevonc.2025.104648_bib37","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104648_bib38","first-page":"JCO2302019","article-title":"Phase I trial of GD2.CART cells augmented with constitutive interleukin-7 receptor for treatment of high-grade pediatric CNS tumors","author":"Lin","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104648_bib39","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tranon.2019.11.006","article-title":"B7-H3 as a prognostic biomarker and therapeutic target in pediatric central nervous system tumors","volume":"13","author":"Maachani","year":"2020","journal-title":"Transl. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104648_bib40","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-024-03035-1","article-title":"Enhancing pediatric access to cell and gene therapies","volume":"30","author":"Mackall","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104648_bib41","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104648_bib42","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104648_bib43","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","author":"Majzner","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104648_bib44","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"15_","key":"10.1016\/j.critrevonc.2025.104648_bib45","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1200\/JCO.2016.34.15_suppl.3011","article-title":"Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104648_bib46","article-title":"Safety and efficacy of dinutuximab in the treatment of neuroblastoma: a review","volume":"28","author":"Mohd","year":"2023","journal-title":"J. Res Med Sci."},{"key":"10.1016\/j.critrevonc.2025.104648_bib47","article-title":"Chimeric antigen receptor T cell therapy in oncology - pipeline at a glance: analysis of the clinicaltrials.gov database","author":"Moreno","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104648_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1200914","article-title":"ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype","volume":"13","author":"Moreno-Cortes","year":"2023","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104648_bib49","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104648_bib50","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","article-title":"Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy","volume":"10","author":"Nazha","year":"2020","journal-title":"Front. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104648_bib51","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1002\/cam4.3083","article-title":"Sponsorship of oncology clinical trials in the United States according to age of eligibility","volume":"9","author":"Neel","year":"2020","journal-title":"Cancer Med."},{"issue":"26","key":"10.1016\/j.critrevonc.2025.104648_bib52","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104648_bib53","unstructured":"Health NIo. Inclusion of children in clinical research: change in NIH definition. Notice number NOT-OD-16-010 National Institutes of Health, Bethesda, MD[Google Scholar]. 2015."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104648_bib54","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.4049\/jimmunol.0804279","article-title":"Differential but direct abolishment of human regulatory T cell suppressive capacity by various TLR2 ligands","volume":"184","author":"Oberg","year":"2010","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104648_bib55","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","article-title":"A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells","volume":"12","author":"Pul\u00e8","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2025.104648_bib56","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol. Ther. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104648_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28083356","article-title":"Targeting B7-H3-A novel strategy for the design of anticancer agents for extracranial pediatric solid tumors treatment","volume":"28","author":"Rasic","year":"2023","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104648_bib58","doi-asserted-by":"crossref","first-page":"799","DOI":"10.4251\/wjgo.v13.i8.799","article-title":"B7 homologue 3 as a prognostic biomarker and potential therapeutic target in gastrointestinal tumors","volume":"13","author":"Rasic","year":"2021","journal-title":"World J. Gastrointest. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104648_bib59","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.clinthera.2023.08.022","article-title":"Exploring barriers to pediatric cancer clinical trials: the role of a networked, just-in-time study program","volume":"45","author":"Rivers","year":"2023","journal-title":"Clin. Ther."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104648_bib60","doi-asserted-by":"crossref","first-page":"8825","DOI":"10.1002\/cam4.5627","article-title":"Changing incentives to ACCELERATE drug development for paediatric cancer","volume":"12","author":"de Rojas","year":"2023","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104648_bib61","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","article-title":"The promise and potential pitfalls of chimeric antigen receptors","volume":"21","author":"Sadelain","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104648_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2020.151483","article-title":"Cytoplasmic expression of B7-H3 and membranous EpCAM expression are associated with higher grade and survival outcomes in patients with clear cell renal cell carcinoma","volume":"46","author":"Saeednejad Zanjani","year":"2020","journal-title":"Ann. Diagn. Pathol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104648_bib63","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00262-024-03685-7","article-title":"Incorporating IL7 receptor alpha signaling in the endodomain of B7H3-targeting chimeric antigen receptor T cells mediates antitumor activity in glioblastoma","volume":"73","author":"Sakunrangsit","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2025.104648_bib64","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","author":"Shah","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104648_bib65","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","article-title":"Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells","volume":"7","author":"Shum","year":"2017","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104648_bib66","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/jnci\/djad115","article-title":"Counts, incidence rates, and trends of pediatric cancer in the United States, 2003-2019","volume":"115","author":"Siegel","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104648_bib67","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104648_bib68","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood.2020005185","article-title":"Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR\/Cas9-mediated TCR knockout CAR","volume":"136","author":"Stenger","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104648_bib69","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2024.13171","article-title":"CAR\u2011T cell therapy: a breakthrough in traditional cancer treatment strategies (Review)","volume":"29","author":"Sun","year":"2024","journal-title":"Mol. Med Rep."},{"key":"10.1016\/j.critrevonc.2025.104648_bib70","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol. Ther. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104648_bib71","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/14737140.2022.2032664","article-title":"The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs","volume":"22","author":"Zettler","year":"2022","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.critrevonc.2025.104648_bib72","article-title":"CAR-T cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104648_bib73","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3340\/jkns.2019.0255","article-title":"Survival association and cell cycle effects of B7H3 in neuroblastoma","volume":"63","author":"Zhang","year":"2020","journal-title":"J. Korean Neurosurg. Soc."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104648_bib74","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104648_bib75","first-page":"4315","article-title":"High expression of B7\u2011H2 or B7\u2011H3 is associated with poor prognosis in hepatocellular carcinoma","volume":"19","author":"Zheng","year":"2019","journal-title":"Mol. Med Rep."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T06:25:02Z","timestamp":1744784702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825000368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":75,"alternative-id":["S1040842825000368"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104648","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T-cell therapy landscape in pediatric, adolescent and young adult oncology \u2013 A comprehensive analysis of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104648","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104648"}}